JP2012121809A - Method for producing polycyclic compound and intermediate thereof - Google Patents
Method for producing polycyclic compound and intermediate thereof Download PDFInfo
- Publication number
- JP2012121809A JP2012121809A JP2009043266A JP2009043266A JP2012121809A JP 2012121809 A JP2012121809 A JP 2012121809A JP 2009043266 A JP2009043266 A JP 2009043266A JP 2009043266 A JP2009043266 A JP 2009043266A JP 2012121809 A JP2012121809 A JP 2012121809A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- formula
- compound
- compound represented
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C1=**(CCC[C@]2c3ccccc3N)C2=*1 Chemical compound *C1=**(CCC[C@]2c3ccccc3N)C2=*1 0.000 description 4
- WMNVXYBPTOMTPG-UHFFFAOYSA-N CC/C(/N/C=N\CC(C)C)=C(\[N]#CC(C)C)/OC Chemical compound CC/C(/N/C=N\CC(C)C)=C(\[N]#CC(C)C)/OC WMNVXYBPTOMTPG-UHFFFAOYSA-N 0.000 description 1
- WDOZZAMJVNXVJE-WEVVVXLNSA-N NNC(/C(/c1ccccc1C(F)(F)F)=C/CCI)=O Chemical compound NNC(/C(/c1ccccc1C(F)(F)F)=C/CCI)=O WDOZZAMJVNXVJE-WEVVVXLNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/30—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
- C07C243/32—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
本発明は、多環式化合物の製造法およびその中間体に関する。更に詳細には、本発明は、アミロイドベータ(以下Aβという)が原因となるアルツハイマー病、ダウン症などの神経変性疾患の治療に有効なAβ産生抑制剤として有用な化合物である、(8S)−2−{(E)−2−[6−メトキシ−5−(4−メチル−1H−イミダゾール−1−イル)ピリジン−2−イル]ビニル}−8−[2−(トリフルオロメチル)フェニル]−5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[1,5−a]ピリジンまたはその塩の製造法、およびその製造のための有用な新規中間体に関する。 The present invention relates to a method for producing a polycyclic compound and an intermediate thereof. More specifically, the present invention is a compound useful as an Aβ production inhibitor effective for the treatment of neurodegenerative diseases such as Alzheimer's disease and Down syndrome caused by amyloid beta (hereinafter referred to as Aβ), (8S) -2 -{(E) -2- [6-Methoxy-5- (4-methyl-1H-imidazol-1-yl) pyridin-2-yl] vinyl} -8- [2- (trifluoromethyl) phenyl]- The present invention relates to a method for producing 5,6,7,8-tetrahydro [1,2,4] triazolo [1,5-a] pyridine or a salt thereof, and a useful new intermediate for the production thereof.
特許文献1には、下記式
特許文献2には、下記式
また、特許文献3には、下記式
で表される化合物がAβ産生抑制作用を示すこと、およびそれら化合物の製造方法が開示されている。
Patent Document 3 discloses the following formula:
That the compound represented by the formula shows an Aβ production inhibitory action, and a method for producing these compounds is disclosed.
特許文献1から3に記載された化合物とは化学構造が相違する化合物であって、Aβが原因となるアルツハイマー病、ダウン症などの神経変性疾患の治療に有効な化合物として、本出願人は、下記式(I)
従って、本発明の課題は、式(I)の化合物またはその塩の工業的に十分に有利な製造法およびその製造に用いる中間体を提供することにある。
As a compound having a chemical structure different from the compounds described in Patent Documents 1 to 3 and effective for the treatment of neurodegenerative diseases such as Alzheimer's disease and Down's disease caused by Aβ, Formula (I)
Accordingly, an object of the present invention is to provide an industrially sufficiently advantageous production method of a compound of the formula (I) or a salt thereof and an intermediate used for the production thereof.
そこで、本発明者らは、上記の課題を解決することを目的として鋭意検討の結果、本発明を見出すに至った。
すなわち本発明は、
(1)下記式(II)
(2)下記式(IV)
(3)下記式(V)
(4)Xが臭素原子またはヨウ素原子であり、Lが塩素原子または臭素原子である、上記(1)ないし(3)記載の製造法、
(5)Xが臭素原子であり、Lが塩素原子である、上記(1)ないし(3)記載の製造法、
(6)下記式(II)
(7)Xが臭素原子である、上記(6)記載の化合物またはその塩、
(8)下記式(III)
(9)下記式(IV)
(10)下記式(V)
(11)Lが塩素原子である、上記(10)記載の化合物またはその塩
に関する。
Therefore, the present inventors have found the present invention as a result of intensive studies aimed at solving the above problems.
That is, the present invention
(1) The following formula (II)
(2) The following formula (IV)
(3) The following formula (V)
(4) The production method according to the above (1) to (3), wherein X is a bromine atom or an iodine atom, and L is a chlorine atom or a bromine atom.
(5) The production method according to the above (1) to (3), wherein X is a bromine atom and L is a chlorine atom,
(6) The following formula (II)
(7) The compound or salt thereof according to (6), wherein X is a bromine atom,
(8) The following formula (III)
(9) The following formula (IV)
(10) The following formula (V)
(11) The compound or a salt thereof according to the above (10), wherein L is a chlorine atom.
本発明により、Aβ産生抑制剤として有用である、(8S)−2−{(E)−2−[6−メトキシ−5−(4−メチル−1H−イミダゾール−1−イル)ピリジン−2−イル]ビニル}−8−[2−(トリフルオロメチル)フェニル]−5,6,7,8−[1,2,4]トリアゾロ[1,5−a]ピリジンまたはその塩を工業的に有利に製造することができる。また、このために有用な新規合成中間体を提供できる。 According to the present invention, (8S) -2-{(E) -2- [6-methoxy-5- (4-methyl-1H-imidazol-1-yl) pyridin-2-, which is useful as an Aβ production inhibitor Yl] vinyl} -8- [2- (trifluoromethyl) phenyl] -5,6,7,8- [1,2,4] triazolo [1,5-a] pyridine or a salt thereof industrially advantageous Can be manufactured. Moreover, a novel synthetic intermediate useful for this purpose can be provided.
以下、本発明の製造法およびそのための新規中間体について詳細に説明する。
以下の説明において、式(I)で表される化合物を、化合物(I)と記載することもある。他の化合物についても、同様に記載することもある。
本発明においてハロゲン原子とは、フッ素原子、塩素原子、臭素原子またはヨウ素原子を意味し、好ましくは臭素原子またはヨウ素原子を意味する。
また本発明において脱離基とは、フッ素原子、塩素原子、臭素原子およびヨウ素原子等のハロゲン原子を意味し、好ましくは塩素原子または臭素原子を意味する。
Hereinafter, the production method of the present invention and a novel intermediate therefor will be described in detail.
In the following description, the compound represented by formula (I) may be referred to as compound (I). Other compounds may be described in the same manner.
In the present invention, the halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a bromine atom or an iodine atom.
In the present invention, the leaving group means a halogen atom such as a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, preferably a chlorine atom or a bromine atom.
本発明の製造法およびそのための新規中間体は、以下の反応スキームによって表される。
本発明におけるカップリング反応(上記反応スキームにおける工程1)は通常、パラジウム触媒、および塩基の存在下に行われる(例えばR.F.Heck、「Org.Reactions」、1982年、27巻、p.345を参照)。ここでは通常、化合物(II)に対して、化合物(III)は通常0.7ないし1.5当量用いられ、好ましくは0.8ないし1.2当量用いられる。パラジウム触媒は0価または二価のパラジウム化合物が用いられ、0価のパラジウム化合物としては、トリス(ジベンジリデンアセトン)ジパラジウム(0)が、二価のパラジウム化合物としては酢酸パラジウム(II)が好ましく用いられる。また好ましくは三価のホスフィン化合物が配位子として併せて用いられる。もっとも好ましくはパラジウム化合物としてトリス(ジベンジリデンアセトン)ジパラジウム(0)が、配位子としてトリ(オルト−トリル)ホスフィンが用いられる。パラジウム触媒の使用量は、化合物(II)に対して、パラジウムとして0.001ないし0.5当量、好ましくは0.005ないし0.2当量が用いられる。使用する塩基としてはトリエチルアミン、ジイソプロピルエチルアミン等の有機塩基、炭酸カリウム等の無機塩基が通常用いられ、好ましくはジイソプロピルエチルアミンが用いられる。塩基の使用量は、化合物(II)に対して、1ないし10当量が用いられ、好ましくは1ないし5当量が用いられる。反応溶媒は使用してもしなくてもいいが、使用する場合は反応を阻害しない限り特別の制限はなく、好ましくはN,N−ジメチルホルムアミドが用いられる。反応温度は室温ないし溶媒の沸点で行われ、好ましくは50ないし150℃、より好ましくは80ないし120℃で行われる。また本反応は、窒素、アルゴンなどの不活性ガス雰囲気下でも好ましく行うことができる。好ましい反応条件においては、本反応は1ないし24時間で完結する。 The coupling reaction in the present invention (Step 1 in the above reaction scheme) is usually performed in the presence of a palladium catalyst and a base (for example, RF Heck, “Org. Reactions”, 1982, Vol. 27, p. 345). Here, compound (III) is usually used in an amount of 0.7 to 1.5 equivalents, preferably 0.8 to 1.2 equivalents, relative to compound (II). As the palladium catalyst, a zero-valent or divalent palladium compound is used, and as the zero-valent palladium compound, tris (dibenzylideneacetone) dipalladium (0) is preferable, and as the divalent palladium compound, palladium (II) acetate is preferable. Used. Preferably, a trivalent phosphine compound is also used as a ligand. Most preferably, tris (dibenzylideneacetone) dipalladium (0) is used as the palladium compound, and tri (ortho-tolyl) phosphine is used as the ligand. The palladium catalyst is used in an amount of 0.001 to 0.5 equivalent, preferably 0.005 to 0.2 equivalent, as palladium, relative to compound (II). As the base to be used, an organic base such as triethylamine or diisopropylethylamine, or an inorganic base such as potassium carbonate is usually used, and diisopropylethylamine is preferably used. The amount of the base used is 1 to 10 equivalents, preferably 1 to 5 equivalents, relative to compound (II). The reaction solvent may or may not be used, but when used, there is no particular limitation as long as the reaction is not inhibited, and N, N-dimethylformamide is preferably used. The reaction temperature is room temperature to the boiling point of the solvent, preferably 50 to 150 ° C, more preferably 80 to 120 ° C. This reaction can also be preferably carried out in an inert gas atmosphere such as nitrogen or argon. Under preferable reaction conditions, the reaction is completed in 1 to 24 hours.
本発明におけるサンドマイヤー反応(上記反応スキームにおける工程2)は、式(IV)の化合物に、通常、亜硝酸ナトリウム等の亜硝酸塩と酸とを用いてジアゾニウム化合物とした後、該ジアゾニウム化合物とハロゲン化銅とを反応させることによって行うことができる。あるいは、式(IV)の化合物に、ハロゲン化銅の存在下、ハロゲン化メチレンの存在下あるいは非存在下、亜硝酸エステルを反応させて行われる。
式(IV)の化合物に、通常水溶媒中、酸の存在下亜硝酸ナトリウム等の亜硝酸塩を反応させてジアゾニウム化合物とした後、通常単離することなく、得られたジアゾニウム化合物とハロゲン化銅とを反応させることによって行うことができる。使用する酸としては、ハロゲン化水素酸が式(IV)の化合物に対して通常1.5ないし3当量用いられ、好ましくは1.8ないし2.2当量用いられる。使用する亜硝酸塩としては、亜硝酸ナトリウムまたは亜硝酸カリウムが、式(IV)の化合物に対して、通常0.8ないし1.2当量用いられ、好ましくは0.9ないし1.1当量用いられる。使用するハロゲン化銅としては、二臭化銅またはヨウ化第一銅が、1ないし10当量が用いられ、好ましくは2ないし5当量が用いられる。通常、上記ハロゲン化反応が臭素化の場合、酸として臭化水素酸が二臭化銅とともに用いられ、ヨウ素化の場合、酸としてヨウ化水素酸がヨウ化第一銅とともに用いられる。また反応は、通常、無溶媒または水もしくは式(IV)の化合物に対して1ないし10当量のハロゲン化水素を含む水溶媒中、ハロゲン化銅を攪拌しながらジアゾニウム化合物を加えて反応させる。ジアゾニウム化合物を得る反応は通常−10ないし0℃で行われ、ハロゲン化の反応は通常20ないし100℃で行われる。好ましい条件においては、本反応は通常0.5ないし12時間で完結する。
式(IV)の化合物に、ハロゲン化銅の存在下、ハロゲン化メチレンの存在下あるいは非存在下、亜硝酸エステルを反応させる場合には、ハロゲン化銅は一価または二価で、式(IV)の化合物に対して、0.5ないし10当量が用いられる。ハロゲン化メチレンは必要に応じて、式(IV)の化合物に対して、1ないし10当量が用いられる。使用するハロゲン化メチレンとしては、ジブロモメタンまたはジヨードメタンが好ましい。亜硝酸エステルは、式(IV)の化合物に対して、1ないし5当量が用いられる。好ましくはテトラヒドロフラン、ジオキサン、アセトニトリル等の有機溶媒中、上記ハロゲン化反応が臭素化の場合は、式(IV)の化合物に対して、2ないし10当量の二臭化銅の存在下、上記ハロゲン化反応がヨウ素化の場合は、式(IV)の化合物に対して、0.1ないし2当量のヨウ化第一銅および1ないし5当量のジヨードメタンの存在下、式(IV)の化合物に対して、1.5ないし3当量の亜硝酸イソアミルを反応させて行われる。反応温度は0ないし150℃、好ましくは50ないし100℃で行われる。好ましい条件においては、本反応は0.5ないし12時間で完結する。
In the Sandmeyer reaction (step 2 in the above reaction scheme) in the present invention, the compound of formula (IV) is usually made into a diazonium compound using a nitrite such as sodium nitrite and an acid, and then the diazonium compound and a halogen are used. It can be performed by reacting with copper chloride. Alternatively, the reaction is carried out by reacting the compound of formula (IV) with a nitrite in the presence of copper halide, in the presence or absence of methylene halide.
The compound of formula (IV) is reacted with a nitrite such as sodium nitrite in the presence of an acid in an aqueous solvent to form a diazonium compound, and the resulting diazonium compound and copper halide are usually not isolated. It can be performed by reacting. As the acid to be used, hydrohalic acid is usually used in an amount of 1.5 to 3 equivalents, preferably 1.8 to 2.2 equivalents, relative to the compound of formula (IV). As the nitrite used, sodium nitrite or potassium nitrite is usually used in an amount of 0.8 to 1.2 equivalents, preferably 0.9 to 1.1 equivalents, relative to the compound of formula (IV). As the copper halide to be used, 1 to 10 equivalents, preferably 2 to 5 equivalents, of copper dibromide or cuprous iodide are used. Usually, when the halogenation reaction is bromination, hydrobromic acid is used as an acid together with copper dibromide. In the case of iodination, hydroiodic acid is used as an acid together with cuprous iodide. The reaction is usually carried out by adding a diazonium compound while stirring the copper halide in an aqueous solvent containing no solvent or water or 1 to 10 equivalents of a hydrogen halide with respect to the compound of formula (IV). The reaction for obtaining the diazonium compound is usually carried out at -10 to 0 ° C, and the halogenation reaction is usually carried out at 20 to 100 ° C. Under preferable conditions, this reaction is usually completed in 0.5 to 12 hours.
When the compound of formula (IV) is reacted with a nitrite in the presence of copper halide, in the presence or absence of methylene halide, the copper halide is monovalent or divalent, and the compound of formula (IV ) Is used in an amount of 0.5 to 10 equivalents. The methylene halide is used in an amount of 1 to 10 equivalents based on the compound of the formula (IV), if necessary. The halogenated methylene used is preferably dibromomethane or diiodomethane. The nitrite is used in an amount of 1 to 5 equivalents relative to the compound of formula (IV). Preferably, when the halogenation reaction is bromination in an organic solvent such as tetrahydrofuran, dioxane or acetonitrile, the halogenation is carried out in the presence of 2 to 10 equivalents of copper dibromide with respect to the compound of formula (IV). When the reaction is iodination, relative to the compound of formula (IV) in the presence of 0.1 to 2 equivalents of cuprous iodide and 1 to 5 equivalents of diiodomethane, relative to the compound of formula (IV) 1.5 to 3 equivalents of isoamyl nitrite are reacted. The reaction temperature is 0 to 150 ° C, preferably 50 to 100 ° C. Under preferable conditions, this reaction is completed in 0.5 to 12 hours.
本発明における環形成反応(上記反応スキームにおける工程3)は、通常カルボン酸ヒドラジド化合物(V)と、シアナミド(NH2CN)、重炭酸アミノグアニジンまたはS−エチルイソチオウレア臭化水素酸塩等のグアニジン化剤とを、酸の存在下反応させ、次いで塩基の存在下、反応させることにより行われる。使用するグアニジン化剤としてはシアナミドが好ましく用いられる。グアニジン化剤の使用量は、式(V)の化合物に対して、1ないし20当量、好ましくは2ないし10当量を用いる。使用する酸としてはp−トルエンスルホン酸、メタンスルホン酸等の有機酸、塩酸、硫酸等の無機酸が用いられるが、好ましくはp−トルエンスルホン酸が用いられる。酸の使用量は、式(V)の化合物に対して、0.5ないし3当量、好ましくは1ないし2当量が用いられる。使用する塩基としてはトリエチルアミン、ジイソプロピルエチルアミン等の有機塩基、炭酸カリウム等の無機塩基が用いられるが、好ましくはトリエチルアミンが用いられる。塩基の使用量は、式(V)の化合物に対して、2ないし20当量、好ましくは5ないし15当量が用いられる。反応溶媒はエタノール、イソプロピルアルコール、アセトニトリルまたは水、あるいはこれらの混合溶媒が用いられるが、好ましくはエタノールが用いられる。反応温度は、30ないし120℃で行われるが、好ましくは50ないし100℃で行われる。好ましい条件においては、本反応は酸処理段階が1ないし24時間、塩基処理段階が5ないし120時間で完結する。 The ring-forming reaction in the present invention (Step 3 in the above reaction scheme) is usually performed by using a carboxylic acid hydrazide compound (V), cyanamide (NH 2 CN), aminoguanidine bicarbonate, S-ethylisothiourea hydrobromide, or the like. The reaction is carried out by reacting the guanidine agent in the presence of an acid and then in the presence of a base. As the guanidine agent to be used, cyanamide is preferably used. The amount of the guanidine agent used is 1 to 20 equivalents, preferably 2 to 10 equivalents, relative to the compound of formula (V). As the acid to be used, organic acids such as p-toluenesulfonic acid and methanesulfonic acid, and inorganic acids such as hydrochloric acid and sulfuric acid are used, and preferably p-toluenesulfonic acid is used. The amount of the acid used is 0.5 to 3 equivalents, preferably 1 to 2 equivalents, relative to the compound of formula (V). As the base to be used, an organic base such as triethylamine or diisopropylethylamine, or an inorganic base such as potassium carbonate is used, but triethylamine is preferably used. The base is used in an amount of 2 to 20 equivalents, preferably 5 to 15 equivalents, relative to the compound of formula (V). As the reaction solvent, ethanol, isopropyl alcohol, acetonitrile or water, or a mixed solvent thereof is used, and ethanol is preferably used. The reaction temperature is 30 to 120 ° C., preferably 50 to 100 ° C. Under preferred conditions, the reaction is completed in 1 to 24 hours for the acid treatment step and 5 to 120 hours for the base treatment step.
本発明の製造法において用いる化合物(II)、(III)、(IV)および(V)は新規化合物である。化合物(III)は、後述する実施例4の1)および2)において記載の方法によって製造することができる。また、脱離基であるLが塩素原子である化合物(V)は、後述する実施例1の1)から3)において記載の方法によって製造することができる。脱離基であるLが他のハロゲン原子である化合物(V)は、実施例1の2)において用いられている1−クロロ−3−ヨードプロパンを、対応する1−ハロ−3−ヨードプロパンもしくは1,3−ジブロモプロパンに替えて同様の反応を行うことによって製造することができる。 Compounds (II), (III), (IV) and (V) used in the production method of the present invention are novel compounds. Compound (III) can be produced by the method described in 1) and 2) of Example 4 described later. Further, the compound (V) in which L as a leaving group is a chlorine atom can be produced by the method described in 1) to 3) of Example 1 described later. Compound (V) in which L as a leaving group is another halogen atom is obtained by replacing 1-chloro-3-iodopropane used in 2) of Example 1 with the corresponding 1-halo-3-iodopropane. Alternatively, it can be produced by carrying out the same reaction in place of 1,3-dibromopropane.
本発明において製造される式(I)の化合物、およびその製造に使用される中間体は塩であってもよく、通常の塩形成工程を加えることによって塩とすることができる。塩としては具体的には、硫酸塩、硝酸塩、リン酸塩、塩酸塩もしくは臭化水素酸塩などの無機酸塩、酢酸塩、マレイン酸塩、酒石酸塩、フマル酸塩もしくはクエン酸塩などの有機カルボン酸塩、またはメタンスルホン酸塩、トルエンスルホン酸塩もしくはカンファースルホン酸塩などの有機スルホン酸塩などが挙げられる。 The compound of the formula (I) produced in the present invention and the intermediate used in the production thereof may be a salt, and can be converted into a salt by adding a usual salt forming step. Specific examples of the salt include inorganic acid salts such as sulfate, nitrate, phosphate, hydrochloride or hydrobromide, acetate, maleate, tartrate, fumarate or citrate. Examples thereof include organic carboxylates or organic sulfonates such as methanesulfonate, toluenesulfonate, and camphorsulfonate.
以下に実施例を挙げて本発明をより詳細に説明するが、これらは例示的なものであって、本発明にかかる製造方法は以下の具体例に制限されるものではない。
なお、下記実施例中で示される略号は以下のとおりである。
THF:テトラヒドロフラン
MTBE:メチル ターシャリーブチル エーテル
DMF:N,N−ジメチルホルムアミド
The present invention will be described in more detail with reference to the following examples, but these are illustrative, and the production method according to the present invention is not limited to the following specific examples.
In addition, the symbol shown in the following Example is as follows.
THF: Tetrahydrofuran MTBE: Methyl tertiary butyl ether DMF: N, N-dimethylformamide
(2S)−5−クロロ−2−[2−(トリフルオロメチル)フェニル]ペンタン酸ヒドラジドの合成
1)(4S)−4−フェニル−3−{[2−(トリフルオロメチル)フェニル]アセチル}−1,3−オキサゾリン−2−オンの合成
NMR (varian 400MHz)
1H−NMR (CDCl3)δ(ppm):4.34(dd,J=4.0,8.8Hz,1H),4.4(s,2H),4.76(dd,J=8.8,9.2Hz,1H),5.44(dd,J=3.6,8.8Hz,1H),7.21(d,J=7.6Hz,1H),7.26−7.40(m,6H),7.46(dd,J=7.6,7.6Hz,1H),7.62(d,J=8.0Hz,1H)
Synthesis of (2S) -5-chloro-2- [2- (trifluoromethyl) phenyl] pentanoic acid hydrazide
1) Synthesis of (4S) -4-phenyl-3-{[2- (trifluoromethyl) phenyl] acetyl} -1,3-oxazolin-2-one
NMR (variant 400MHz)
1 H-NMR (CDCl 3 ) δ (ppm): 4.34 (dd, J = 4.0, 8.8 Hz, 1H), 4.4 (s, 2H), 4.76 (dd, J = 8) .8, 9.2 Hz, 1H), 5.44 (dd, J = 3.6, 8.8 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.26-7. 40 (m, 6H), 7.46 (dd, J = 7.6, 7.6 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H)
2)(4S)−3−{(2S)−5−クロロ−2−[2−(トリフルオロメチル)フェニル]ペンタノイル}−4−フェニル−1,3−オキサゾリン−2−オンの合成
得られた粗結晶16g(34.6mmol)にエタノール(48mL)を加え、50℃に加温して完全に溶かした。室温まで徐冷し、生じた結晶をろ過、冷エタノール(15mL)で洗い、減圧乾燥して標記化合物を14.9g(含量96.3%,100%de)、収率97.8%で得た。
NMR(varian 400MHz)
1H−NMR(CDCL3)δ(ppm):1.64−1.72(m,1H),1.74−1.84(m,1H),1.98−2.09(m,1H),2.12−2.23(m,1H),3.44−3.53(m,2H),4.31(dd,J=3.2,8.8Hz,1H),4.68(dd,J=8.8,8.8Hz,1H),5.36(dd,J=3.2,8.8Hz,1H),5.54(dd,J=4.8,9.2Hz,1H),7.28−7.34(m,2H),7.35−7.46(m,4H),7.52−7.59(m,1H),7.60−7.68(m,2H).
2) Synthesis of (4S) -3-{(2S) -5-chloro-2- [2- (trifluoromethyl) phenyl] pentanoyl} -4-phenyl-1,3-oxazolin-2-one
Ethanol (48 mL) was added to 16 g (34.6 mmol) of the obtained crude crystals, and the mixture was heated to 50 ° C. and completely dissolved. The resulting crystals were filtered, washed with cold ethanol (15 mL), and dried under reduced pressure to obtain 14.9 g (content 96.3%, 100% de) of the title compound in a yield of 97.8%. It was.
NMR (variant 400MHz)
1 H-NMR (CDCL3) δ (ppm): 1.64-1.72 (m, 1H), 1.74-1.84 (m, 1H), 1.98-2.09 (m, 1H) 2.12-2.23 (m, 1H), 3.44-3.53 (m, 2H), 4.31 (dd, J = 3.2, 8.8 Hz, 1H), 4.68 ( dd, J = 8.8, 8.8 Hz, 1H), 5.36 (dd, J = 3.2, 8.8 Hz, 1H), 5.54 (dd, J = 4.8, 9.2 Hz, 1H), 7.28-7.34 (m, 2H), 7.35-7.46 (m, 4H), 7.52-7.59 (m, 1H), 7.60-7.68 ( m, 2H).
3)(2S)−5−クロロ−2−[2−(トリフルオロメチル)フェニル]ペンタン酸ヒドラジドの合成
NMR(varian 400MHz)
1H−NMR(CDCL3)δ(ppm):1.54−1.68(m、1H),1.75−1.89(m,1H),1.92−2.04(m,1H),2.20−2.36(m,1H),3.45−3.59(m,2H),3.72(t,J=7.6Hz,1H),6.82(brs,1H),7.38(t,J=7.6Hz,1H),7.56(t,J=7.6Hz,1H),7.66(d,J=8.0Hz,1H),7.52(d,J=7.6Hz,1H).
3) Synthesis of (2S) -5-chloro-2- [2- (trifluoromethyl) phenyl] pentanoic acid hydrazide
NMR (variant 400MHz)
1 H-NMR (CDCL3) δ (ppm): 1.54-1.68 (m, 1H), 1.75-1.89 (m, 1H), 1.92-2.04 (m, 1H) 2.20-2.36 (m, 1H), 3.45-3.59 (m, 2H), 3.72 (t, J = 7.6 Hz, 1H), 6.82 (brs, 1H) , 7.38 (t, J = 7.6 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.52 ( d, J = 7.6 Hz, 1H).
(8S)−8−[2−(トリフルオロメチル)フェニル]−5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[1,5−a]ピリジン−2−アミンの合成
1H−NMR(400MHz,CDCl3)δ(ppm):1.65−1.91(m,1H),2.03−2.14(m,1H),2.15−2.24(m,1H),2.34−2.41(m,1H),4.06(s,2H),4.08−4.13(m,2H),4.51(dd,J=9.2,6.4Hz,1H),7.08(d,J=8.0Hz,1H),7.36(dd,J=8.0,7.6Hz,1H),7.48(dd,J=7.6,7.2Hz,1H),7.69(d,J=7.2Hz,1H).
Synthesis of (8S) -8- [2- (trifluoromethyl) phenyl] -5,6,7,8-tetrahydro [1,2,4] triazolo [1,5-a] pyridin-2-amine
1 H-NMR (400 MHz, CDCl 3 ) δ (ppm): 1.65-1.91 (m, 1H), 2.03-2.14 (m, 1H), 2.15-2.24 (m , 1H), 2.34-2.41 (m, 1H), 4.06 (s, 2H), 4.08-4.13 (m, 2H), 4.51 (dd, J = 9.2). , 6.4 Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 7.36 (dd, J = 8.0, 7.6 Hz, 1H), 7.48 (dd, J = 7.6, 7.2 Hz, 1H), 7.69 (d, J = 7.2 Hz, 1H).
(8S)−2−ブロモ−8−[2−(トリフルオロメチル)フェニル]−5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[1,5−a]ピリジンの合成
1H−NMR(400MHz,CDCl3)δ(ppm):1.87−1.97(m,1H),2.09−2.20(m,1H),2.21−2.30(m,1H),2.39−2.50(m,1H),4.21−4.38(m,2H),4.61(dd,J=9.2,6.0Hz,1H),6.99(d,J=8.0Hz,1H),7.38(dd,J=8.0,7.2Hz,1H),7.49(dd,J=8.0,7.2Hz,1H),7.69(d,J=8.0Hz,1H)
Synthesis of (8S) -2-bromo-8- [2- (trifluoromethyl) phenyl] -5,6,7,8-tetrahydro [1,2,4] triazolo [1,5-a] pyridine
1 H-NMR (400 MHz, CDCl 3 ) δ (ppm): 1.87-1.97 (m, 1H), 2.09-2.20 (m, 1H), 2.21-2.30 (m , 1H), 2.39-2.50 (m, 1H), 4.21-4.38 (m, 2H), 4.61 (dd, J = 9.2, 6.0 Hz, 1H), 6 .99 (d, J = 8.0 Hz, 1H), 7.38 (dd, J = 8.0, 7.2 Hz, 1H), 7.49 (dd, J = 8.0, 7.2 Hz, 1H) ), 7.69 (d, J = 8.0 Hz, 1H)
2−メトキシ−3−(4−メチル−1H−イミダゾール−1−イル)−6−ビニルピリジンの合成
1)2−メトキシ−3−(4−メチル−1H−イミダゾール−1−イル)−6−[(トリメチルシリル)エチニル]ピリジンの合成
ESI−MS;m/z 286[M++H].
1H−NMR(CDCl3)δ(ppm):0.19(s,3H),0.20(s,3H),2.29(s,3H),4.04(s,3H),6.97(s,1H),7.16(d,J=8.0Hz,1H),7.46(d,J=8.0Hz,1H),7.79(s,1H)
Synthesis of 2-methoxy-3- (4-methyl-1H-imidazol-1-yl) -6-vinylpyridine 1) 2-methoxy-3- (4-methyl-1H-imidazol-1-yl) -6 Synthesis of [(trimethylsilyl) ethynyl] pyridine
ESI-MS; m / z 286 [M + + H].
1 H-NMR (CDCl 3 ) δ (ppm): 0.19 (s, 3H), 0.20 (s, 3H), 2.29 (s, 3H), 4.04 (s, 3H), 6 .97 (s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.79 (s, 1H)
2)6−エチニル−2−メトキシ−3−(4−メチル−1H−イミダゾール−1−イル)ピリジンの合成
ESI−MS;m/z 214[M++H].
1H−NMR(CDCl3)δ(ppm):2.30(s,3H),3.19(s,3H),4.05(s,3H),6.97(s,1H),7.20(d,J=8.0Hz,1H),7.50(d,J=8.0Hz,1H),7.80(s,1H)
2) Synthesis of 6-ethynyl-2-methoxy-3- (4-methyl-1H-imidazol-1-yl) pyridine
ESI-MS; m / z 214 [M + + H].
1 H-NMR (CDCl 3 ) δ (ppm): 2.30 (s, 3H), 3.19 (s, 3H), 4.05 (s, 3H), 6.97 (s, 1H), 7 .20 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.80 (s, 1H)
3)2−メトキシ−3−(4−メチル−1H−イミダゾール−1−イル)−6−ビニルピリジンの合成
ESI−MS;m/z 216[M++H].
1H−NMR(CDCl3)δ(ppm):2.30(s,3H),4.04(s,3H),5.48(dd,J=10.5,1.6Hz,1H),6.31(dd,J=17.2,1.6Hz,1H),6.71(dd,J=17.2,10.5Hz,1H),6.92(d,J=7.9Hz,1H),6.96(s,1H),7.48(d,J=7.9Hz,1H),7.76(s,1H)
3) Synthesis of 2-methoxy-3- (4-methyl-1H-imidazol-1-yl) -6-vinylpyridine
ESI-MS; m / z 216 [M + + H].
1 H-NMR (CDCl 3 ) δ (ppm): 2.30 (s, 3H), 4.04 (s, 3H), 5.48 (dd, J = 10.5, 1.6 Hz, 1H), 6.31 (dd, J = 17.2, 1.6 Hz, 1H), 6.71 (dd, J = 17.2, 10.5 Hz, 1H), 6.92 (d, J = 7.9 Hz, 1H), 6.96 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.76 (s, 1H)
(8S)−2−{(E)−2−[6−メトキシ−5−(4−メチル−1H−イミダゾール−1−イル)ピリジン−2−イル]ビニル}−8−[2−(トリフルオロメチル)フェニル]−5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[1,5−a]ピリジンの合成
ESI−MS;m/z 481[M++H].
1H−NMR(400MHz,CDCl3)δ(ppm):1.90−2.01(m,1H),2.12−2.23(m,1H),2.23−2.30(m,1H),2.29(s,3H),2.43−2.53(m,1H),4.03(s,3H),4.32−4.37(m,2H),4.61(dd,J=8.4,5.6Hz,1H),6.93(d,J=8.0Hz,1H),6.95(s,1H),7.02(d,J=7.6Hz,1H),7.39(dd,J=8.4,7.6Hz,1H),7.43(d,J=15.6Hz,1H),7.46(d,J=8.0Hz,1H),7.49(dd,J=8.4,8.0Hz,1H),7.64(d,J=15.6Hz,1H),7.73(d,J=8.0Hz,1H),7.77(s,1H).
(8S) -2-{(E) -2- [6-Methoxy-5- (4-methyl-1H-imidazol-1-yl) pyridin-2-yl] vinyl} -8- [2- (trifluoro Synthesis of methyl) phenyl] -5,6,7,8-tetrahydro [1,2,4] triazolo [1,5-a] pyridine
ESI-MS; m / z 481 [M + + H].
1 H-NMR (400 MHz, CDCl 3 ) δ (ppm): 1.90-2.01 (m, 1H), 2.12-2.23 (m, 1H), 2.23-2.30 (m , 1H), 2.29 (s, 3H), 2.43-2.53 (m, 1H), 4.03 (s, 3H), 4.32-4.37 (m, 2H), 4. 61 (dd, J = 8.4, 5.6 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.95 (s, 1H), 7.02 (d, J = 7 .6 Hz, 1H), 7.39 (dd, J = 8.4, 7.6 Hz, 1H), 7.43 (d, J = 15.6 Hz, 1H), 7.46 (d, J = 8. 0 Hz, 1H), 7.49 (dd, J = 8.4, 8.0 Hz, 1H), 7.64 (d, J = 15.6 Hz, 1H), 7.73 (d, J = 8.0 Hz) , 1H), 7.77. s, 1H).
本発明は、Aβ産生抑制剤として有用である(8S)−2−{(E)−2−[6−メトキシ−5−(4−メチル−1H−イミダゾール−1−イル)ピリジン−2−イル]ビニル}−8−[2−(トリフルオロメチル)フェニル]−5,6,7,8−[1,2,4]トリアゾロ[1,5−a]ピリジンまたはその塩の製造方法を提供する。またこの製造のために有用な新規合成中間体を提供する。 The present invention is useful as an Aβ production inhibitor (8S) -2-{(E) -2- [6-methoxy-5- (4-methyl-1H-imidazol-1-yl) pyridin-2-yl. ] Vinyl} -8- [2- (trifluoromethyl) phenyl] -5,6,7,8- [1,2,4] triazolo [1,5-a] pyridine or a salt thereof . Also provided are novel synthetic intermediates useful for this preparation.
Claims (11)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009043266A JP2012121809A (en) | 2009-02-26 | 2009-02-26 | Method for producing polycyclic compound and intermediate thereof |
PCT/JP2010/052808 WO2010098332A1 (en) | 2009-02-26 | 2010-02-24 | Method for producing polycyclic compound and intermediate for same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009043266A JP2012121809A (en) | 2009-02-26 | 2009-02-26 | Method for producing polycyclic compound and intermediate thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2012121809A true JP2012121809A (en) | 2012-06-28 |
Family
ID=42665538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009043266A Pending JP2012121809A (en) | 2009-02-26 | 2009-02-26 | Method for producing polycyclic compound and intermediate thereof |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2012121809A (en) |
WO (1) | WO2010098332A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
UA110688C2 (en) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Bicyclic pirydynony |
AU2016214102B2 (en) | 2015-02-03 | 2018-09-27 | Pfizer Inc. | Novel cyclopropabenzofuranyl pyridopyrazinediones |
CN107434780B (en) * | 2016-05-26 | 2020-08-07 | 上海韬勤生物医药科技有限公司 | Preparation method of AR-13324 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200716104A (en) * | 2005-06-01 | 2007-05-01 | Wyeth Corp | Tricyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
WO2007102580A1 (en) * | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | Polycyclic cinnamide derivative |
WO2009028588A1 (en) * | 2007-08-31 | 2009-03-05 | Eisai R & D Management Co., Ltd. | Polycyclic compound |
-
2009
- 2009-02-26 JP JP2009043266A patent/JP2012121809A/en active Pending
-
2010
- 2010-02-24 WO PCT/JP2010/052808 patent/WO2010098332A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010098332A1 (en) | 2010-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018202625B2 (en) | Processes for preparing JAK inhibitors and related intermediate compounds | |
CN109678791B (en) | 1- (2, 4-difluorophenyl) -2, 2-difluoro-2- (5-substituted pyridine-2-yl) ethanone and preparation method thereof | |
JP2021536471A (en) | Methyl 6- (2,4-dichlorophenyl) -5- [4-[(3S) -1- (3-fluoropropyl) pyrrolidine-3-yl] oxyphenyl] -8,9-dihydro-7H-benzo [7] ] Salt of Annelen-2-carboxylate and its manufacturing method | |
RU2636943C2 (en) | Anti-viral compound production | |
EP3398952B1 (en) | Synthesis process of ruxolitinib | |
JP5603998B2 (en) | Method for preparing benzoxabolol | |
JP2017031180A (en) | Process for preparing substituted 5-fluoro-1h-pyrazolopyridines | |
JP2020097562A (en) | Synthesis of pyrido[2,3-d]pyrimidine-7(8h)-one | |
JP2012121809A (en) | Method for producing polycyclic compound and intermediate thereof | |
US8436200B2 (en) | Process for making (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4- iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione and intermediates thereof | |
WO2015018289A1 (en) | Novel method for synthesizing key intermediate of apixaban | |
US9969735B2 (en) | Process for making tricyclic lactam compounds | |
US20200207750A1 (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
WO2010098496A1 (en) | Process for producing tetrahydrotriazolopyridine derivative | |
JP2019534313A (en) | Resolution of optically active diazaspiro [4.5] decane derivatives | |
EP3848361A1 (en) | Method of producing tetracyclic compound | |
JP2004525927A (en) | Method for producing lansoprazole and its intermediate | |
JP2007291101A (en) | Process for preparing pyridine compound | |
CA2562578C (en) | Process for production of pyrazole-fused ring derivatives | |
WO2007020960A1 (en) | Process for producing carbapenem derivatives through reactions without isolating intermediates | |
AU2014221468B2 (en) | Substituted (R)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-enecarboxylic acid (variants) and ester thereof, method for producing and using same | |
WO2007037303A1 (en) | Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof | |
JP2003286285A (en) | Method for producing pyridone compound and intermediate for the same | |
JP2003321468A (en) | Method for producing pyridone compound and intermediate for the compound | |
JPWO2017056338A1 (en) | Method for producing pyrazole derivative |